Last updated: February 15, 2026
Overview of the Drug
NDC 72305-0112 corresponds to Cannabidiol (CBD) Oral Solution, marketed under the brand name Epidiolex. It is approved for rare conditions such as Lennox-Gastaut syndrome and Dravet syndrome. Its approval by the U.S. FDA in 2018 positions it as a leading pharmaceutical CBD product for specific neurological disorders.
Market Size and Trends
- Market Growth (2018–2022): The global cannabis-derived pharmaceuticals market was valued at approximately $1.1 billion in 2018 and grew at a compound annual growth rate (CAGR) of around 36% to reach $4.5 billion by 2022.[1]
- U.S. Market Share: Epidiolex captured a significant portion of the U.S. pharmaceutical CBD market due to its FDA approval. The retail sales of Epidiolex in 2022 exceeded $400 million in the U.S., accounting for nearly 90% of the pharmaceutical CBD market segment.[2]
Competitive Landscape
- Key Competitors: Other CBD-based products include GW Pharmaceuticals’ derivative formulations, unapproved hemp extracts, and emerging biosimilar or generic options pending patent expirations.
- Patent and Exclusivity: Epidiolex benefits from exclusivity periods extending into the mid-2020s, limiting immediate competition.[3]
- Pricing Strategies: The current list price for Epidiolex in the U.S. is approximately $32,500 annually for a typical adult dosage.[4]
Price Projections
- Current Pricing (2023): The average wholesale price (AWP) remains around $/unit, with monthly retail costs averaging $2,708.[4]
- Near-term Future (2024–2026): Patent protections and top-market position support stable pricing, with possible slight reduction due to generic entry. Expected annual retail price range: $30,000–$33,000.
- Long-term Outlook (2027 and beyond): Once patent expiration occurs (expected around 2025–2026), generic versions could enter the market, pressuring prices downward by an estimated 20–30%. Prices might fall to $20,000–$25,000 annually.[5]
Regulatory and Market Access Impact
- Regulatory Changes: Pending rescheduling or broader approval for additional indications could expand the market, increasing revenue opportunities. Conversely, restrictions on cannabis derivatives could limit growth.
- Market Access: Coverage and reimbursement policies vary; private insurers predominantly cover Epidiolex for approved indications, sustaining high prices.
Potential Market Expansion
- Additional Indications: Clinical trials for epilepsy subtypes, neurodegenerative diseases, and other neurological disorders could broaden use.
- Global Markets: Europe and Canada see rising demand, with national health systems gradually integrating Epidiolex into formulary coverage, potentially doubling or tripling revenue streams by 2030.
Risks and Limitations
- Patent Cliff: Generic entry will likely reduce prices and margins.
- Regulatory Environment: Shifts in drug scheduling could enable new competitors or restrict sales.
- Market Competition: Emerging non-prescription hemp-derived CBD products threaten the premium positioning of Epidiolex.
Summary Table of Price Dynamics
| Year |
Estimated Average Price |
Description |
| 2023 |
~$32,500/year |
Current list price |
| 2024–2026 |
$30,000–$33,000/year |
Expected stability pre-generic entry |
| 2027+ |
$20,000–$25,000/year |
Post-patent expiration, potential decline |
Key Takeaways
- Epidiolex (NDC 72305-0112) leads the pharmaceutical CBD market for specific neurological disorders.
- It generated over $400 million in U.S. sales in 2022, with stable pricing driven by patent exclusivity.
- Prices are expected to decline by 20–30% within 2–3 years of patent expiry.
- Market expansion depends on regulatory approvals and reimbursement policies; global demand remains strong.
- Competition from generic formulations and non-prescription products presents downward pressure on pricing.
FAQs
-
When is the patent expiration for Epidiolex?
Patent protection extends into 2025–2026, after which generics are expected to enter the market.
-
What factors influence Epidiolex's price trajectory?
Patent status, regulatory changes, approval for additional indications, and market competition.
-
Are cheaper alternatives available?
Non-FDA approved hemp extracts and biosimilars are available but lack regulatory approval for approved indications.
-
How might regulatory shifts affect the market?
Rescheduling or approval of new indications could expand sales; restrictions could limit access.
-
What are the prospects for global expansion?
Increasing adoption in Europe and Canada; uncertain in emerging markets due to regulatory variability.
Citations
[1] Research and Markets. "Global Cannabis Pharmaceuticals Market," 2022.
[2] IQVIA. "U.S. Cannabis and CBD Market Report," 2022.
[3] U.S. FDA. "Epidiolex Approval and Patent Data," 2018.
[4] GoodRx. "Epidiolex Pricing Overview," 2023.
[5] MarketWatch. "Post-Patent Generic Entry and CBD Market," 2022.
